SG55007A1 - Mycophenolate mofetil high dose oral suspensions - Google Patents

Mycophenolate mofetil high dose oral suspensions

Info

Publication number
SG55007A1
SG55007A1 SG1996001682A SG1996001682A SG55007A1 SG 55007 A1 SG55007 A1 SG 55007A1 SG 1996001682 A SG1996001682 A SG 1996001682A SG 1996001682 A SG1996001682 A SG 1996001682A SG 55007 A1 SG55007 A1 SG 55007A1
Authority
SG
Singapore
Prior art keywords
high dose
mycophenolate mofetil
oral suspensions
dose oral
agent
Prior art date
Application number
SG1996001682A
Other languages
English (en)
Inventor
Deborah M Lidgate
Li-Hua Wang-Kessler
Bindu Joshi
Sayee G Hegde
Leo Gu
Original Assignee
Syntrex U S A Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Syntrex U S A Inc filed Critical Syntrex U S A Inc
Publication of SG55007A1 publication Critical patent/SG55007A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1611—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1682—Processes
    • A61K9/1694—Processes resulting in granules or microspheres of the matrix type containing more than 5% of excipient

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Transplantation (AREA)
  • Rheumatology (AREA)
  • Virology (AREA)
  • Pain & Pain Management (AREA)
  • Dermatology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Cosmetics (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Pyridine Compounds (AREA)
  • Harvesting Machines For Root Crops (AREA)
SG1996001682A 1993-10-01 1994-09-27 Mycophenolate mofetil high dose oral suspensions SG55007A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US13034393A 1993-10-01 1993-10-01

Publications (1)

Publication Number Publication Date
SG55007A1 true SG55007A1 (en) 1998-12-21

Family

ID=22444241

Family Applications (1)

Application Number Title Priority Date Filing Date
SG1996001682A SG55007A1 (en) 1993-10-01 1994-09-27 Mycophenolate mofetil high dose oral suspensions

Country Status (27)

Country Link
US (1) US5688529A (cs)
EP (2) EP0721335B1 (cs)
JP (1) JP3844491B2 (cs)
CN (1) CN1089583C (cs)
AT (1) ATE303143T1 (cs)
AU (1) AU678303B2 (cs)
BR (1) BR9407728A (cs)
CZ (2) CZ301771B6 (cs)
DE (1) DE69434474T2 (cs)
DK (1) DK0721335T3 (cs)
ES (1) ES2248793T3 (cs)
FI (2) FI116773B (cs)
HU (1) HU228672B1 (cs)
IL (1) IL111116A (cs)
LT (1) LT4099B (cs)
LV (1) LV11428B (cs)
NO (1) NO310673B1 (cs)
NZ (1) NZ274678A (cs)
PL (1) PL177323B1 (cs)
PT (1) PT721335E (cs)
RO (1) RO115412B1 (cs)
RU (1) RU2150942C1 (cs)
SG (1) SG55007A1 (cs)
TW (1) TW427914B (cs)
UA (1) UA39962C2 (cs)
WO (1) WO1995009626A1 (cs)
ZA (1) ZA947683B (cs)

Families Citing this family (79)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6436425B1 (en) 1988-11-16 2002-08-20 Mdv Technologies, Inc. Method and non-gelling composition for inhibiting post-surgical adhesions
US5346703A (en) 1990-08-07 1994-09-13 Mediventures, Inc. Body cavity drug delivery with thermo-irreversible polyoxyalkylene and ionic polysaccharide gels
US5318780A (en) * 1991-10-30 1994-06-07 Mediventures Inc. Medical uses of in situ formed gels
US5843470A (en) 1995-10-06 1998-12-01 Mdv Technologies, Inc. Method and composition for inhibiting post-surgical adhesions
ID18663A (id) 1996-04-12 1998-04-30 Novartis Ag Komposisi farmasi berlapis enterik
US5759579A (en) * 1996-12-05 1998-06-02 American Home Products Corporation Pharmaceutical suspension systems
JP2001526246A (ja) * 1997-12-23 2001-12-18 アライアンス・ファーマスーティカル・コーポレイション 薬剤送達及び／又は癒着防止のための方法及び組成物
WO2000015210A2 (en) * 1998-09-14 2000-03-23 Vertex Pharmaceuticals Incorporated Use of mycophenol acid and its derivatives for the treatment of virus diseases
US6410255B1 (en) * 1999-05-05 2002-06-25 Aurora Biosciences Corporation Optical probes and assays
NZ529505A (en) 1999-05-14 2005-09-30 Nereus Pharmaceuticals Inc Novel interleukin-1 and tumor necrosis factor-alpha modulators synthesis of said modulators and methods of using said modulators
US6726922B1 (en) 1999-06-28 2004-04-27 Minu, L.L.C. Process and composition for temporarily suppressing pain
HK1049185A1 (zh) 2000-02-23 2003-05-02 Invitrogen Corporation 可改萤光蛋白
JP4395549B2 (ja) * 2000-11-16 2010-01-13 ザ レジェンツ オブ ザ ユニヴァースティ オブ カリフォルニア 薬物及び発酵生成物の発見のための海洋放線菌分類群
FR2819721B1 (fr) * 2001-01-19 2005-02-04 L M D Traitement des escarres avec sucre non metabolisable et un absorbant polymerique
BRPI0116865B8 (pt) 2001-01-23 2021-05-25 Gador Sa composição compreendendo bisfosfonatos para prevenção e/ou tratamento de doenças metabólicas dos ossos, processo para preparar tal composição e uso desta
DK1232746T3 (da) * 2001-02-14 2006-10-23 Forte Iq B V Farmaceutisk sammensætning indeholdende xanthan gummi
DE60100389T2 (de) 2001-07-11 2004-05-19 Apr Applied Pharma Research S.A. Fettlösliche Substanzen enthaltende Granulate und Verfahren zu ihrer Herstellung
EP1465620A4 (en) * 2001-10-02 2006-01-25 Smithkline Beecham Corp NEW COMPOSITION OF CARVEDILOL
GB0124953D0 (en) * 2001-10-17 2001-12-05 Novartis Ag Organic Compounds
US7176232B2 (en) 2002-06-24 2007-02-13 The Regents Of The University Of California Salinosporamides and methods for use thereof
US20040127435A1 (en) * 2002-08-02 2004-07-01 Regents Of The University Of California Uses for inhibitors of inosine monophosphate dehydrogenase
US7112581B2 (en) * 2002-09-27 2006-09-26 Nereus Pharmaceuticals, Inc. Macrocyclic lactams
GB0307553D0 (en) * 2003-04-01 2003-05-07 Novartis Ag Organic compounds
US20050187170A1 (en) * 2003-06-16 2005-08-25 Biocryst Pharmaceuticals, Inc. Enhancing the efficiency of RNA polymerase inhibitors by using inosine monophosphate dehydrogenase inhibitors
EP2441767B1 (en) * 2003-06-20 2015-06-10 The Regents of The University of California Salinosporamides and methods for use thereof
WO2005002572A2 (en) * 2003-06-20 2005-01-13 Nereus Pharmaceuticals, Inc. Use of [3.2.0] heterocyclic compounds and analogs thereof for the treatment of cancer, inflammation and infectious diseases
CA2445420A1 (en) 2003-07-29 2005-01-29 Invitrogen Corporation Kinase and phosphatase assays
US7619059B2 (en) 2003-07-29 2009-11-17 Life Technologies Corporation Bimolecular optical probes
US7727752B2 (en) 2003-07-29 2010-06-01 Life Technologies Corporation Kinase and phosphatase assays
CA2538755C (en) * 2003-09-12 2013-04-16 Ryukakusan Co. Ltd. Granular jelly drink capable of masking bitterness
AR045957A1 (es) * 2003-10-03 2005-11-16 Novartis Ag Composicion farmaceutica y combinacion
US7087369B2 (en) * 2003-12-17 2006-08-08 The Regents Of The University Of California Cornea preservation medium
AU2005206560A1 (en) * 2004-01-23 2005-08-04 Nereus Pharmaceuticals, Inc. Bis-indole pyrroles useful as antimicrobials agents
TW200613294A (en) * 2004-04-26 2006-05-01 Teva Gyogyszergyar Reszvenytarsasag Process for preparation of mycophenolic acid and ester derivatives thereof
CA2555461A1 (en) * 2004-04-27 2005-11-10 Teva Gyogyszergyar Zartkoeruen Mukoedo Reszvenytarsasag Process for preparation of mycophenolate mofetil and other esters of mycophenolic acid
JP2007535559A (ja) * 2004-04-30 2007-12-06 ネレアス ファーマシューティカルズ インコーポレイテッド ［３．２．０］複素環式化合物及びその使用法
US7579371B2 (en) 2004-04-30 2009-08-25 Nereus Pharmaceuticals, Inc. Methods of using [3.2.0] heterocyclic compounds and analogs thereof
US20050266031A1 (en) 2004-05-25 2005-12-01 Jay Dickerson Pharmaceutical suspension composition
US20110104186A1 (en) 2004-06-24 2011-05-05 Nicholas Valiante Small molecule immunopotentiators and assays for their detection
CA2572223C (en) * 2004-06-25 2014-08-12 The Johns Hopkins University Angiogenesis inhibitors
CA2573784A1 (en) * 2004-07-20 2006-02-02 Teva Gyogyszergyar Zartkoruen Mukodo Reszvenytarsasag Crystalline mycophenolate sodium
US20060051428A1 (en) * 2004-09-03 2006-03-09 Nelson Ayala Aspartame and citrate flavored phosphate salt laxative
US20060093629A1 (en) * 2004-10-29 2006-05-04 Buehler Gail K Dye-free pharmaceutical suspensions and related methods
KR101282191B1 (ko) * 2004-12-03 2013-07-08 다나-파버 캔서 인스티튜트 인크. 신생물성 질환을 치료하는 조성물 및 방법
US20080281111A1 (en) * 2005-04-26 2008-11-13 Sandor Molnar Process for preparation of mycophenolate mofetil and other esters of mycophenolic acid
KR20080035650A (ko) 2005-07-21 2008-04-23 니리어스 파마슈티컬즈, 인코퍼레이션 인터루킨―1 및 종양괴사인자―ａ 조정자들, 이러한조정자들의 합성 및 이들의 사용 방법
US20070082061A1 (en) * 2005-10-07 2007-04-12 Nelson Ayala Reduction of saltiness with sweeteners
KR20080094788A (ko) * 2006-02-13 2008-10-24 노파르티스 아게 고복용량의 미코페놀산(엠피에이)
US7985429B2 (en) 2006-03-03 2011-07-26 C. B. Fleet Company, Inc. Flavored colonic cleansing system
GB0612809D0 (en) * 2006-06-28 2006-08-09 Univ Sunderland Formulation
US7998510B2 (en) * 2006-08-17 2011-08-16 C. B. Fleet Company, Inc. Low dose colonic cleansing system
FR2911506B1 (fr) * 2007-01-18 2009-07-03 Ceva Sante Animale Sa Compositions pharmaceutiques destinees a une administration par voie orale sous forme de suspensions aqueuses stabilisees
US7824698B2 (en) * 2007-02-02 2010-11-02 Nereus Pharmaceuticals, Inc. Lyophilized formulations of Salinosporamide A
US8999395B2 (en) * 2007-02-09 2015-04-07 Ceva Sante Animale Pharmaceutical compositions for oral administration in the form of stabilised aqueous suspensions
USD683210S1 (en) 2007-03-01 2013-05-28 C.B. Fleet Company, Inc. Container for colonic cleansing kit
US20090017167A1 (en) * 2007-07-11 2009-01-15 Herbalife International Inc. Mixture and beverage made therefrom for protecting cellular hydration
CA2701777C (en) * 2007-10-12 2015-04-21 Ryukakusan Co. Ltd. Granular jelly beverage for medication and process for producing the same
TW200932240A (en) 2007-10-25 2009-08-01 Astellas Pharma Inc Pharmaceutical composition containing lipophilic substance which inhibits IL-2 production
US8394816B2 (en) * 2007-12-07 2013-03-12 Irene Ghobrial Methods of using [3.2.0] heterocyclic compounds and analogs thereof in treating Waldenstrom's Macroglobulinemia
CN102089312A (zh) 2008-05-12 2011-06-08 尼瑞斯药品公司 作为蛋白酶体抑制剂的Salinosporamide衍生物
JP2011527339A (ja) * 2008-07-09 2011-10-27 アスプレバ インターナショナル リミテッド 眼障害を処置するためのミコフェノール酸ナトリウムのｐＨ特異的な溶液
CN101671706B (zh) * 2009-09-05 2013-09-18 山东新时代药业有限公司 一种霉酚酸发酵过程中补糖方法
RU2012113844A (ru) * 2009-09-10 2013-10-20 Биал-Портела Энд К.А., С.А. Пероральные суспензионные лекарственные формы ацетата эсликарбазепина
WO2011117883A1 (en) * 2010-03-23 2011-09-29 Alkem Laboratories Ltd. Pharmaceutical composition of mycophenolate mofetil and process for preparing thereof
US8669281B1 (en) 2013-03-14 2014-03-11 Alkermes Pharma Ireland Limited Prodrugs of fumarates and their use in treating various diseases
KR102085557B1 (ko) 2013-03-14 2020-03-06 엘커메스 파마 아일랜드 리미티드 푸마레이트의 프로드럭 및 다양한 질환을 치료하는데 있어서의 이들의 용도
US9168246B2 (en) 2013-06-27 2015-10-27 Veloxis Pharmaceutical A/S Regimen for suppressing organ rejection
WO2015127450A1 (en) 2014-02-24 2015-08-27 Alkermes Pharma Ireland Limited Sulfonamide and sulfinamide prodrugs of fumarates and their use in treating various diseases
EP3628640B1 (en) 2014-09-02 2023-08-09 Hub Therapeutics Methods of making a deuterated or a non-deuterated molecule and pharmaceutical formulations for treatment
CA2963923A1 (en) 2014-10-08 2016-04-14 Pacific Northwest Research Institute Methods and compounds for increasing the potency of antifungal agents
EP3222278B1 (en) * 2014-10-24 2023-06-14 Launx Biomedical Co., Ltd. Use of azelnidipine in preparing medicinal composition for treating cancers
US10603299B2 (en) 2016-06-02 2020-03-31 Steven Baranowitz Prevention and treatment of viral infections
CA3026241A1 (en) 2016-06-02 2017-12-07 Steven Baranowitz Prevention and treatment of viral infections
US12011429B2 (en) 2016-06-02 2024-06-18 Steven Baranowitz Prevention and treatment of viral infections
US11918684B2 (en) * 2017-03-13 2024-03-05 Liqmeds Worldwide Limited Pharmaceutical composition of oral suspension of immunosuppressive agents
CN112533614A (zh) 2018-03-28 2021-03-19 美国康宝莱国际公司 多糖的乙酰化
EP3836898A2 (en) 2018-08-18 2021-06-23 FTF Pharma Private Limited Pharmaceutical suspension for oral dosage
CN112315962B (zh) * 2020-11-17 2022-03-29 北京化工大学 霉酚酸在治疗和预防柯萨奇病毒感染中的应用
CN114931552A (zh) * 2021-02-12 2022-08-23 浙江贝灵生物医药有限公司 一种口服碱性溶媒组合物及其制备方法与应用

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1157100A (en) * 1966-09-27 1969-07-02 Ici Ltd Pharmaceutical Compositions
ZA717826B (en) * 1970-11-27 1973-06-27 Lilly Co Eli Psoriasis treatment with mycophenolic acid
US3880995A (en) * 1973-05-14 1975-04-29 Lilly Co Eli Treatment of arthritis with mycophenolic acid and derivatives
CA1146866A (en) * 1979-07-05 1983-05-24 Yamanouchi Pharmaceutical Co. Ltd. Process for the production of sustained release pharmaceutical composition of solid medical material
CH653550A5 (de) * 1981-10-20 1986-01-15 Sandoz Ag Pharmazeutische zusammensetzung zur verzoegerten freigabe eines medikamentes im mundbereich.
US4727069A (en) 1987-01-30 1988-02-23 Syntex (U.S.A.) Inc. Heterocyclic aminoalkyl esters of mycophenolic acid, derivatives thereof and pharmaceutical compositions
US4753935A (en) 1987-01-30 1988-06-28 Syntex (U.S.A.) Inc. Morpholinoethylesters of mycophenolic acid and pharmaceutical compositions
KR100215167B1 (ko) * 1990-08-10 1999-08-16 위샤르트 아이 시 면역 억제 조성물
US5247083A (en) * 1992-07-10 1993-09-21 Syntex (U.S.A.) Inc. Direct esterification of mycophenolic acid

Also Published As

Publication number Publication date
CZ95496A3 (en) 1996-06-12
HUT73675A (en) 1996-09-30
WO1995009626A1 (en) 1995-04-13
LV11428A (lv) 1996-08-20
JPH09509648A (ja) 1997-09-30
LT96039A (en) 1996-10-25
DE69434474D1 (de) 2005-10-06
CZ301771B6 (cs) 2010-06-16
PL177323B1 (pl) 1999-10-29
FI117502B (fi) 2006-11-15
CN1089583C (zh) 2002-08-28
IL111116A0 (en) 1994-11-28
AU7920594A (en) 1995-05-01
FI961466L (fi) 1996-04-01
HU228672B1 (en) 2013-05-28
HU9600838D0 (en) 1996-05-28
NO961325L (no) 1996-04-01
TW427914B (en) 2001-04-01
EP1475091A1 (en) 2004-11-10
RO115412B1 (ro) 2000-02-28
JP3844491B2 (ja) 2006-11-15
FI20060003L (fi) 2006-01-02
DK0721335T3 (da) 2006-01-09
EP0721335A1 (en) 1996-07-17
BR9407728A (pt) 1997-02-12
NZ274678A (en) 1999-07-29
PT721335E (pt) 2005-11-30
ES2248793T3 (es) 2006-03-16
NO961325D0 (no) 1996-04-01
LT4099B (en) 1997-01-27
HK1012583A1 (en) 1999-08-06
FI961466A0 (fi) 1996-04-01
PL313772A1 (en) 1996-07-22
RU2150942C1 (ru) 2000-06-20
NO310673B1 (no) 2001-08-13
DE69434474T2 (de) 2006-05-18
ATE303143T1 (de) 2005-09-15
CZ291231B6 (cs) 2003-01-15
CN1132479A (zh) 1996-10-02
IL111116A (en) 1998-04-05
LV11428B (en) 1996-12-20
EP0721335B1 (en) 2005-08-31
ZA947683B (en) 1996-04-01
AU678303B2 (en) 1997-05-22
UA39962C2 (uk) 2001-07-16
US5688529A (en) 1997-11-18
FI116773B (fi) 2006-02-28

Similar Documents

Publication Publication Date Title
HU9600838D0 (en) Mycophenolate mofetil high dose oral suspensions
NZ233102A (en) Aqueous ibuprofen compositions containing suspension stabilisers, taste masking ingredients and buffer acids to give a ph between 1.5 and 3.5
ES2104605T3 (es) Composiciones estables de acido ascorbico.
NZ234143A (en) Aqueous pharmaceutical suspension formulation for administering substantially insoluble pharmaceutical agents
CA2000168A1 (en) Oral compositions
AU6006786A (en) Use of N-(4-phenoxy-2, 6-diisopropylphenyl)-N'-tert- butylthiourea for controlling white flies
AU564201B2 (en) Sucralfate suspension
HUT43828A (en) Process for producing 1,1-disubstituted cyclopropan derivatives and pharmaceutical and/or fungicide compositions containing them as active agents
GB2248185B (en) Pharmaceutical compositions containing furan derivatives
HUT43829A (en) Process for producing 1,1-disubstituted cyclopropan derivatives and pharmaceutical and/or fungicide compositions containing them as active agents
ES2001856A6 (es) Una composicion acuosa basica de isotiazolonas n-insustituidas
CA2172506A1 (en) Mycophenolate mofetil and mycophenolic acid high dose oral suspensions
DE3771260D1 (de) Kalziumkarbonatsuspension enthaltende pharmazeutische zusammensetzung.
SE8605050D0 (sv) Anvendning av tetrahydrobensotienylkarbamid-derivat som fungicider
GR3002135T3 (en) Derivatives of n-(methylsulphonylphenylethyl)-2-propenamides and their use as antibiotics
CA2120751A1 (en) Trimethoprim oral liquid
EP0142597A3 (en) Curative composition for buerger's disease
RU93051781A (ru) Бета -фенилизосерин-(2r,3s) и его соли, способ его получения и его применения
AR242777A1 (es) Compuestos insecticidamente activos derivados de n,n'-dibenzoilhidrazina y composicion que los contienen.
UA27821C2 (uk) Похідні ізатину або ізатиноксиму, що мають активність, пов'язану з блокадою рецепторів глутамінової та аспарагінової кислот, спосіб їх одержання, фармацевтична композиція та спосіб лікування